Risk of mortality on and off methadone substitution treatment in primary care: A national cohort study

Addiction

Volumn 111, Issue 1, 2016, Pages 73-82

  Cousins, Gráinne ^a   Boland, Fiona ^a   Courtney, Brenda ^a   Barry, Joseph ^b   Lyons, Suzi ^c   Fahey, Tom ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b ADELAIDE AND MEATH HOSPITAL   (Ireland)

^c HEALTH RESEARCH BOARD   (Ireland)

Author keywords

All cause mortality; Cohort study; Drug related deaths; Maintenance treatment; Methadone; Mortality; Opioid; Supervised consumption

Indexed keywords

METHADONE;

ADOLESCENT; ADULT; AGED; COHORT ANALYSIS; EPIDEMIOLOGY; FEMALE; HUMAN; IRELAND; MALE; MIDDLE AGED; MORTALITY; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PRIMARY HEALTH CARE; PROCEDURES; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; IRELAND; MALE; METHADONE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PRIMARY HEALTH CARE; RISK ASSESSMENT; YOUNG ADULT;

EID: 84945433908     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.13087     Document Type: Article

References (41)

1. Degenhardt L., Bucello C., Mathers B., Briegleb C., Ali H., Hickman M. et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011; 106: 32-51.
2. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2013: Trends and developments. Euro Surveill 2013; 18: 29-47.
3. Bellerose D., Carew A. M., Lyons S. Trends in treated problem drug use in Ireland 2005 to 2010. HRB Trend Series 12. Dublin: Health Research Board; 2011.
4. Farrell M., Barry J. The introduction of the opioid treatment protocol. Dublin: Department of Health, Health Service Executive; 2010.
5. Morgan O., Griffiths C., Toson B., Rooney C., Majeed A., Hickman M. Trends in deaths related to drug misuse in England and Wales, 1993-2004. Health Stat Q 2006; 31: 23-7.
6. Lyons S., Lynn E., Walsh S., Long J. Drug-related deaths and deaths among drug users in Ireland. HRB Trends Series 4. Dublin: Health Research Board; 2014.
7. Mathers B. M., Degenhardt L., Bucello C., Lemon J., Wiessing L., Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ 2013; 91: 102-23.
8. Davoli M., Bargagli A. M., Perucci C. A., Schifano P., Belleudi V., Hickman M. et al. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multisite prospective cohort study. Addiction 2007; 102: 1954-9.
9. Cornish R., Macleod J., Strang J., Vickerman P., Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010; 341: c5475.
10. Cousins G., Teljeur C., Motterlini N., McCowan C., Dimitrov B. D., Fahey T. Risk of drug-related mortality during periods of transition in methadone maintenance treatment: a cohort study. J Subst Abuse Treat 2011; 41: 252-60.
11. Buster M. C., van Brussel G. H., van den Brink W. An increase in overdose mortality during the first 2weeks after entering or re-entering methadone treatment in Amsterdam. Addiction 2002; 97: 993-1001.
12. Degenhardt L., Randall D., Hall W., Law M., Butler T., Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20years: risk factors and lives saved. Drug Alcohol Depend 2009; 105: 9-15.
13. Caplehorn J. R., Drummer O. H. Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Med J Aust 1999; 170: 104-9.
14. Green H., James R. A., Gilbert J. D., Harpas P., Byard R. W. Methadone maintenance programs-a two-edged sword? Am J Forensic Med Pathol 2000; 21: 359-61.
15. Weinrich M., Stuart M. Provision of methadone treatment in primary care medical practices: review of the Scottish experience and implications for US policy. JAMA 2000; 283: 1343-8.
16. Seymour A., Black M., Jay J., Cooper G., Weir C., Oliver J. The role of methadone in drug-related deaths in the west of Scotland. Addiction 2003; 98: 995-1002.
17. Strang J., Hall W., Hickman M., Bird S. M. Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): analyses using OD4 index in England and Scotland. BMJ 2010; 341: c4851.
18. Scottish Office Department of Health, Welsh Office, Social Services Northern Ireland. Drug Misuse and Dependence-Guidelines on Clinical Management. London: Stationery Office; 1999.
19. Brilleman S. L., Salisbury C. Comparing measures of multimorbidity to predict outcomes in primary care: a cross sectional study. Fam Pract 2013; 30: 172-8.
20. Gibson A., Degenhardt L., Mattick R. P., Ali R., White J., O'Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction 2008; 103: 462-8.
21. Bell J., Burrell T., Indig D., Gilmour S. Cycling in and out of treatment; participation in methadone treatment in NSW, 1990-2002. Drug Alcohol Depend 2006; 81: 55-61.
22. Burns L., Randall D., Hall W. D., Law M., Butler T., Bell J. et al. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Addiction 2009; 104: 1363-72.
23. Cao X., Wu Z., Li L., Pang L., Rou K., Wang C. et al. Mortality among methadone maintenance clients in China: a six-year cohort study. PLOS ONE 2013; 8: e82476.
24. McCowan C., Kidd B., Fahey T. Factors associated with mortality in Scottish patients receiving methadone in primary care: retrospective cohort study. BMJ 2009; 338: b2225.
25. Pierce M., Bird S. M., Hickman M., Millar T. National record linkage study of mortality for a large cohort of opioid users ascertained by drug treatment or criminal justice sources in England, 2005-2009. Drug Alcohol Depend 2015; 146: 17-23.
26. Bell J. R., Butler B., Lawrance A., Batey R., Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009; 104: 73-7.
27. Zador D., Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. Addiction 2000; 95: 77-84.
28. Hickman M., Madden P., Henry J., Baker A., Wallace C., Wakefield J. et al. Trends in drug overdose deaths in England and Wales 1993-98: methadone does not kill more people than heroin. Addiction 2003; 98: 419-25.
29. Clausen T., Anchersen K., Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend 2008; 94: 151-7.
30. Nosyk B., MacNab Y. C., Sun H., Fischer B., Marsh D. C., Schechter M. T. et al. Proportional hazards frailty models for recurrent methadone maintenance treatment. Am J Epidemiol 2009; 170: 783-92.
31. Clausen T., Waal H., Thoresen M., Gossop M. Mortality among opiate users: opioid maintenance therapy, age and causes of death. Addiction 2009; 104: 1356-62.
32. Brugal M., Domingo-Salvany A., Puig R., Barrio G., de Olalla P., de la Fuente L. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and AIDS in a cohort of heroin users in Spain. Addiction 2005; 100: 981-9.
33. Gossop M., Marsden J., Stewart D., Treacy S. Change and stability of change after treatment of drug misuse: 2-year outcomes from the National Treatment Outcome Research Study (UK). Addict Behav 2002; 27: 155-66.
34. Hickman M., Carnwath Z., Madden P., Farrell M., Rooney C., Ashcroft R. et al. Drug-related mortality and fatal overdose risk: pilot cohort study of heroin users recruited from specialist drug treatment sites in London. J Urban Health 2003; 80: 274-87.
35. Chen K. W., Berger C. C., Forde D. P., D'Adamo C., Weintraub E., Gandhi D. Benzodiazepine use and misuse among patients in a methadone program. BMC Psychiatry 2011; 11: 90.
36. Bramness J. G., Kornor H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. Drug Alcohol Depend 2007; 90: 203-9.
37. Amato L., Davoli M., Perucci C. A., Ferri M., Faggiano F., Mattick R. P. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005; 28: 321-9.
38. Larance B., Carragher N., Mattick R. P., Lintzeris N., Ali R., Degenhardt L. A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: do stable patients receive more unsupervised doses? Drug Alcohol Depend 2014; 142: 46-55.
39. Bell J. R., Ryan A., Mutch C., Batey R., Rea F. Optimising the benefits of unobserved dose administration for stable opioid maintenance patients: follow-up of a randomised trial. Drug Alcohol Depend 2008; 96: 183-6.
40. Deering D. E., Sheridan J., Sellman J. D., Adamson S. J., Pooley S., Robertson R. et al. Consumer and treatment provider perspectives on reducing barriers to opioid substitution treatment and improving treatment attractiveness. Addict Behav 2011; 36: 636-42.
41. Holland R., Matheson C., Anthony G., Roberts K., Priyardarshi S., Macrae A. et al. A pilot randomised controlled trial of brief versus twice weekly versus standard supervised consumption in patients on opiate maintenance treatment. Drug Alcohol Rev 2012; 31: 483-91.